Adaptive Immune Response Against Corona Virus Vaccination
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Sars Cov 2
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
AICOVI (Adaptive Immune Response against Corona Virus Vaccination) is a prospective clinical study aiming at elucidating the kinetics of vaccine-specific antibody production after COVID-19 vaccination in health care workers at the Greifswald University hospital. Participants regularly received two i...
AICOVI (Adaptive Immune Response against Corona Virus Vaccination) is a prospective clinical study aiming at elucidating the kinetics of vaccine-specific antibody production after COVID-19 vaccination in health care workers at the Greifswald University hospital. Participants regularly received two i.m. doses of BNT162b2 (Comirnaty®, BioNTech/Pfizer) with a time distance of 21 days, or two i.m. doses of ChadOx1 nCov-19 (AZD 1222®, Oxford University/Astra-Zeneca) with a time distance of 12 weeks. Within the study, volunteers donate peripheral blood on each day of vaccination as well as 7 and 14 days after each vaccination, and EDTA plasma and peripheral mononuclear cells (PBMCs) are prepared and stored at -20 °C. The vaccinees are also asked to complete a questionnaire (asking for previous SARS-CoV-2 infection, side effects of the vaccination, and atopies) on each day of blood sampling.
Tracking Information
- NCT #
- NCT04826770
- Collaborators
- Not Provided
- Investigators
- Study Chair: Barbara M. Bröker, Prof. Dr. University Medicine Greifswald, Dept. of Immunology
Get Well Soon